Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials

American Journal of Geriatric Psychiatry

Volumn 23, Issue 12, 2015, Pages 1234-1249

  Ströhle, Andreas ^a   Schmidt, Dietlinde K ^a   Schultz, Florian ^b   Fricke, Nina ^b   Staden, Theresa ^a   Hellweg, Rainer ^a   Priller, Josef ^a,c   Rapp, Michael A ^d   Rieckmann, Nina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Psychologische Hochschule   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Alzheimer dementia; drug; exercise; mild cognitive impairment

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CALCULATION; COCHRANE LIBRARY; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; EFFECT SIZE; FOOD AND DRUG ADMINISTRATION; HUMAN; KINESIOTHERAPY; MEDICATION THERAPY MANAGEMENT; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; PHARMACEUTICAL CARE; PHYSICAL ACTIVITY; POPULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; WEB OF SCIENCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ALZHEIMER DISEASE; COGNITION; EXERCISE THERAPY; HUMANS; MILD COGNITIVE IMPAIRMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84975796456     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2015.07.007     Document Type: Article

References (99)

1. Services UDoHaH: National plan to adress Alzheimer's disease. (online). 2014. Available at http://aspe.hhs.gov/2014-national-alzheimers-disease-plan-available. Accessed November 6, 2015
2. M. Nakanishi, and T. Nakashima Features of the Japanese national dementia strategy in comparison with international dementia policies: how should a national dementia policy interact with the public health- and social-care systems? Alzheimer Dement 10 2014 468 476.e3
3. R.C. Petersen, G.E. Smith, S.C. Waring, and et al. Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308
4. R.C. Petersen Clinical practice. Mild cognitive impairment N Engl J Med 364 2011 2227
5. M.S. Albert, S.T. DeKosky, D. Dickson, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer Dement 7 2011 270 279
6. S.G. Di Santo, F. Prinelli, F. Adorni, and et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease J Alzheimers Dis 35 2013 349 361
7. J.S. Lin, E. O'Connor, R.C. Rossom, and et al. Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 159 2013 601 612
8. E.B. Larson, L. Wang, J.D. Bowen, and et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older Ann Intern Med 144 2006 73 81
9. L.J. Podewils, E. Guallar, L.H. Kuller, and et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study Am J Epidemiol 161 2005 639 651
10. D. Forbes, E.J. Thiessen, C.M. Blake, and et al. Exercise programs for people with dementia Cochrane Database Syst Rev 12 2013 CD006489
11. R.A. Hansen, G. Gartlehner, A.P. Webb, and et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Clin Intervent Aging 3 2008 211 225
12. T.C. Russ, and J.R. Morling Cholinesterase inhibitors for mild cognitive impairment Cochrane Database Syst Rev 9 2012 CD009132
13. N. Gates, M.A. Fiatarone Singh, P.S. Sachdev, and et al. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials Am J Geriatr Psychiatry 21 2013 1086 1097
14. R. Petersen Normal aging, mild cognitive impairment, and early Alzheimer's disease Neurologist 1 1995 326 344
15. J.P.T. Higgins, and D.G. Altman Assessing risk of bias in included studies, in Cochrane Handbook for Systematic Reviews of Interventions 2008 John Wiley & Sons, Ltd 187 241
16. Team RDC: R: A language and enviroment for statistical computing. (online). 2014. Available at http://R-project.org. Accessed October 4, 2014
17. W. Viechtbauer Conducting meta-analyses in R with the metafor package J Stat Software 36 2010 1 48
18. S.B. Morris Estimating effect sizes from pretest-posttest-control group designs Organ Res Methods 11 2008 364 386
19. B.J. Becker Synthesizing standardized mean-change measures Br J Math Stat Psychol 41 1988 257 278
20. M.W. Lipsey, and D.B. Wilson Practical Meta-Analysis 2001 Sage Publications, Inc Thousand Oaks, CA
21. M. Steinberg, J.M. Leoutsakos, L.J. Podewils, and et al. Evaluation of a home-based exercise program in the treatment of Alzheimer's disease: the Maximizing Independence in Dementia (MIND) study Int J Geriatr Psychiatry 24 2009 680 685
22. R. McCarney, P. Fisher, S. Iliffe, and et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial Int J Geriatr Psychiatry 23 2008 1222 1230
23. L.D. Baker, L.L. Frank, K. Foster-Schubert, and et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial Arch Neurol 67 2010 71 79
24. A. Burns, M. Rossor, J. Hecker, and et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial Dement Geriatr Cog Disord 10 1999 237 244
25. H. Feldman, S. Gauthier, J. Hecker, and et al. Erratum: a 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613 620
26. A. Homma, Y. Imai, H. Tago, and et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial Dement Geriatr Cog Disord 25 2008 399 407
27. R.C. Mohs, R.S. Doody, J.C. Morris, and et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 2001 481 488
28. B. Seltzer, P. Zolnouni, M. Nunez, and et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial Arch Neurol 61 2004 1852 1856
29. P.N. Tariot, J.L. Cummings, I.R. Katz, and et al. A randomised, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting J Am Geriatr Soc 49 2001 1590 1599
30. B. Winblad, K. Engedal, H. Soininen, and et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 57 2001 489 495
31. L.V. Hedges, and J.L. Vevea Fixed- and random-effects models in meta-analysis Psychol Methods 3 1998 486 504
32. T. Suzuki, H. Shimada, H. Makizako, and et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment PloS One 8 2013 e61483
33. N.T. Lautenschlager, K.L. Cox, L. Flicker, and et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease JAMA 300 2008 1027 1037
34. R.S. Doody, P.N. Tariot, E. Pfeiffer, and et al. Meta-analysis of six-month memantine trials in Alzheimer's disease Alzheimer Dement 3 2007 7 17
35. B. Winblad, J. Cummings, N. Andreasen, and et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule Int J Geriatr Psychiatry 22 2007 456 467
36. P. Heyn, B.C. Abreu, and K.J. Ottenbacher The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis Arch Physical Med Rehab 85 2004 1694 1704
37. D.E. Barnes, W. Santos-Modesitt, G. Poelke, and et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults JAMA 173 2013 797 804
38. J.C. Davis, S. Bryan, C.A. Marra, and et al. An economic evaluation of resistance training and aerobic training versus balance and toning exercises in older adults with mild cognitive impairment PLoS One 8 2013 e63031
39. L.S. Nagamatsu, T.C. Handy, C.L. Hsu, and et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment Arch Intern Med 172 2012 666 668
40. J.C. Smith, K.A. Nielson, P. Antuono, and et al. Semantic memory functional MRI and cognitive function after exercise intervention in mild cognitive impairment J Alzheimers Dis 37 2013 197 215
41. K. Sugano, M. Yokogawa, S. Yuki, and et al. Effect of cognitive and aerobic training intervention on older adults with mild or no cognitive impairment: a derivative study of the Nakajima project Dement Geriatr Cogn Disord 2 2012 69 80
42. C.M. Nascimento, C.V. Teixeira, L.T. Gobbi, and et al. A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer's disease Rev Bras Fisio 16 2012 197 204
43. K.H. Pitkala, M.M. Poysti, M.L. Laakkonen, and et al. Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial JAMA 173 2013 894 901
44. P. Suttanon, K.D. Hill, C.M. Said, and et al. Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer's disease: a pilot randomized controlled trial Clin Rehabil 27 2013 427 438
45. F.G. Coelho, L.P. Andrade, R.V. Pedroso, and et al. Multimodal exercise intervention improves frontal cognitive functions and gait in Alzheimer's disease: a controlled trial Geriatr Gerontol Int 13 2013 198 203
46. F. Andersen, M. Viitanen, D.S. Halvorsen, and et al. The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design BMC Neurology 12 2012 9
47. H. Naci, and J.P.A. Ioannidis Comparative effectiveness of exercise and drug interventions on mortality outcomes: meta-epidemiological study BMJ 347 2013 f5577
48. B.T. Walsh, S.N. Seidman, R. Sysko, and et al. Placebo response in studies of major depression: variable, substantial, and growing JAMA 287 2002 1840 1847
49. K. Ito, B. Corrigan, K. Romero, and et al. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database J Alzheimer Dis 37 2013 173 183
50. N. Mann, and A. Rosenzweig Can exercise teach us how to treat heart disease? Circulation 126 2012 2625 2635
51. C. Sorenson, H. Naci, J. Cylus, and et al. Evidence of comparative efficacy should have a formal role in European drug approvals BMJ 343 2011 d4849
52. H. Naci, J. Cylus, S. Vandoros, and et al. Raising the bar for market authorisation of new drugs BMJ 345 2012 e4261
53. S.E. Black, R. Doody, H. Li, and et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease Neurology 69 2007 459 469
54. B. Winblad, L. Kilander, S. Eriksson, and et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study Lancet 367 2006 1057 1065
55. C. Courtney, D. Farrell, R. Gray, and et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 2004 2105 2115
56. L. Tune, P.J. Tiseo, J. Ieni, and et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study Am J Geriatr Psychiatry 11 2003 169 177
57. A. Homma, M. Takeda, Y. Imai, and et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan Dement Geriatr Cogn Disord 11 2000 299 313
58. S.L. Rogers, R.S. Doody, R.C. Mohs, and et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study Arch Intern Med 158 1998 1021 1031
59. S.L. Rogers, M.R. Farlow, R.S. Doody, and et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurology 50 1998 136 145
60. S.L. Rogers, and L.T. Friedhoff The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group Dementia 7 1996 293 303
61. A. Burns, R. Bernabei, R. Bullock, and et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial Lancet Neurol 8 2009 39 47
62. K. Rockwood, S. Fay, X. Song, and et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial CMAJ 174 2006 1099 1105
63. H. Brodaty, J. Corey-Bloom, F.C. Potocnik, and et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease Dement Geriatr Cogn Disord 20 2005 120 132
64. K. Rockwood, J. Mintzer, L. Truyen, and et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial J Neurol Neurosurg Psychiatry 71 2001 589 595
65. G.K. Wilcock, S. Lilienfeld, and E. Gaens Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial BMJ 321 2000 145 149
66. D. Wilkinson, and J. Murray Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease Int J Geriatr Psychiatry 16 2001 852 857
67. M.A. Raskind, E.R. Peskind, T. Wessel, and et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension Neurology 54 2000 2261 2268
68. P.N. Tariot, P.R. Solomon, J.C. Morris, and et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group Neurology 54 2000 2269 2276
69. R. Ihl, M. Tribanek, N. Bachinskaya, and et al. Efficacy and tolerability of a once daily formulation of ginkgo biloba extract EGb 761 (R) in Alzheimer's disease and vascular dementia: results from a randomised controlled trial Pharmacopsychiatry 45 2012 41 46
70. O. Napryeyenko, G. Sonnik, and I. Tartakovsky Efficacy and tolerability of ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial J Neurol Sci 283 2009 224 229
71. S. Kanowski, W.M. Herrmann, K. Stephan, and et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia Phytomedicine 4 1997 3 13
72. K. Maurer, R. Ihl, T. Dierks, and et al. Clinical efficacy of ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type J Psychiatr Res 31 1997 645 655
73. N. Herrmann, S. Gauthier, N. Boneva, and et al. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease Int Psychogeriatr 25 2013 919 927
74. N. Wang, X. Chen, D. Geng, and et al. Ginkgo biloba leaf extract improves the cognitive abilities of rats with D-galactose induced dementia J Biomed Res 27 2013 29 36
75. C. Fox, M. Crugel, I. Maidment, and et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial PLoS One 7 2012 e35185
76. S. Bakchine, and H. Loft Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study J Alzheimer Dis 11 2007 471 479
77. C.H. van Dyck, P.N. Tariot, B. Meyers, and et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease Alzheimer Dis Assoc Disord 21 2007 136 143
78. A. Homma, S. Kitamura, and I. Yoshimura Efficacy of memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study) Eur J Neurology 14 2007 49 50
79. Forest: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with moderate-to-severe dementia of the Alzheimer's type. (online). ClinicalTrialsgov, 2006. Available at https://clinicaltrials.gov/ct2/show/NCT00322153. Accessed November 6, 2015
80. Lundbeck: A prospective randomised double-blind parallel-group placebo-controlled study of memantine in Alzheimer's disease. Lundbeck Clinical Trial Registry, 2006. (online). Available at http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/339/CN-00580339/frame.html. Accessed August 2015
81. E.R. Peskind, S.G. Potkin, N. Pomara, and et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial Am Geriatr Psychiatry 14 2006 704 715
82. P.N. Tariot, M.R. Farlow, G.T. Grossberg, and et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JAMA 291 2004 317 324
83. B. Reisberg, R. Doody, A. Stöffler, and et al. Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 2003 13333 13341
84. F. Forette, R. Anand, and G. Gharabawi A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon) Eur J Neurology 6 1999 423 429
85. M. Rosler, R. Anand, A. Cicin-Sain, and et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial BMJ 318 1999 633 638
86. Y. Agid, B. Dubois, R. Anand, and et al. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type Curr Therapeut Res Clin Exper 1998 837 845
87. J.R. Corey-Bloom, J.V. Anand, J. Veach, and et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 55 65
88. B. Winblad, S. Gauthier, L. Scinto, and et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment Neurology 70 2008 2024 2035
89. H.H. Feldman, S. Ferris, B. Winblad, and et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study Lancet Neurol 6 2007 501 512
90. R.C. Petersen, R.G. Thomas, M. Grundman, and et al. Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2005 2379 2388
91. S. Salloway, S. Ferris, A. Kluger, and et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial Neurology 63 2004 651 657
92. A. Vreugdenhil, J. Cannell, A. Davies, and et al. A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial Scand J Caring Sci 26 2012 12 19
93. M. Venturelli, R. Scarsini, and F. Schena Six-month walking program changes cognitive and ADL performance in patients with Alzheimer Am J Alzheimers Dis Other Dement 26 2011 381 388
94. G. Kemoun, M. Thibaud, N. Roumagne, and et al. Effects of a physical training programme on cognitive function and walking efficiency in elderly persons with dementia Dement Geriatr Cogn Disord 29 2010 109 114
95. S. Varela, C. Ayan, J.M. Cancela, and et al. Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study Clin Rehab 26 2012 442 450
96. J.G. van Uffelen, M.J. Chinapaw, W. van Mechelen, and et al. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial Br J Med 42 2008 344 351
97. E.J. Scherder, J. Van Paasschen, J.B. Deijen, and et al. Physical activity and executive functions in the elderly with mild cognitive impairment Aging Ment Health 9 2005 272 280
98. S. Colcombe, and A. Kramer Fitness effects on the cognitive function of older adults: a meta-analytic study Psychol Sci 14 2003 125 130
99. G.M. Cooney, K. Dwan, C.A. Greig, and et al. Exercise for depression Cochrane Database Syst Rev 9 2013 CD004366